

Remarks

Claims 1, 4, 5, 13, 32-34 and 48-70 were pending in the subject application. By way of this amendment, claims 1-48 and 52-70 have been canceled and claims 71-78 are newly added. Thus, claims 49-51 and 71-78 are before the Examiner for consideration. The undersigned avers that no new matter is introduced by this amendment and that support for the newly presented claims can be found in the application and claims as originally filed (see, for example, page 18, about line 15). Accordingly, entry and consideration of the amendment presented herein is respectfully requested. Favorable consideration of the pending claims is also respectfully requested.

Applicants gratefully acknowledge the Examiner's indication of allowable subject matter with respect to the subject invention and have amended the claims to facilitate the allowance of the application. New claims 71-78 have been presented to parallel previously presented claims that provided compositions comprising the allowable peptide-based immunotherapeutic agents and methods of using the same. It is respectfully submitted that the subject amendment does not raise new issues or require consideration of the claims that not previously performed.

In view of the foregoing remarks and amendments to the claims, the applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested. It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants' agreement with or acquiescence in the Examiner's position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

J:\SPO\103\AFResponse-.doc\DNB\ssa


5

Docket No. SPO-103  
Serial No. 09/142,524

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

The applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 NW 41st Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/ssa

OFFICIAL

RECEIVED  
CENTRAL FAX CENTER

SEP 22 2003

J:\Spo\103\AFResponse-.doc\DNB\ssa